Tazemetostat in relapsed/refractory follicular lymphoma: a propensity score–matched analysis of E7438-G000-101 trial outcomes

Purpose: In the tazemetostat E7438-G000-101 trial of relapsed/refractory (R/R) follicular lymphoma (FL), apparent superior efficacy was suggested for mutant-type (MT) EZH2 versus wild-type (WT) status. However, clinical disparities might have contributed to this conclusion. This study aimed to estim...

Descripción completa

Detalles Bibliográficos
Autores principales: Proudman, David G., Gupta, Deepshekhar, Nellesen, Dave, Yang, Jay, Kamp, Beth A., Mamlouk, Khalid, Cheson, Bruce D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2022
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9093865/
https://www.ncbi.nlm.nih.gov/pubmed/35574216
http://dx.doi.org/10.18632/oncotarget.28229

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9093865/
https://www.ncbi.nlm.nih.gov/pubmed/35574216
http://dx.doi.org/10.18632/oncotarget.28229

Ejemplares similares